These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. Deferasirox for managing iron overload in people with myelodysplastic syndrome. Meerpohl JJ; Schell LK; Rücker G; Fleeman N; Motschall E; Niemeyer CM; Bassler D Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD007461. PubMed ID: 25348770 [TBL] [Abstract][Full Text] [Related]
49. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia. Ladis V; Berdousi H; Gotsis E; Kattamis A Br J Haematol; 2010 Dec; 151(5):504-8. PubMed ID: 20950401 [TBL] [Abstract][Full Text] [Related]
50. Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia. Shirley M; Plosker GL Drugs; 2014 Jun; 74(9):1017-27. PubMed ID: 24919862 [TBL] [Abstract][Full Text] [Related]
51. Oral iron chelation and the treatment of iron overload in a pediatric hematology center. Raphael JL; Bernhardt MB; Mahoney DH; Mueller BU Pediatr Blood Cancer; 2009 May; 52(5):616-20. PubMed ID: 19148949 [TBL] [Abstract][Full Text] [Related]
52. Deferasirox. Stumpf JL Am J Health Syst Pharm; 2007 Mar; 64(6):606-16. PubMed ID: 17353569 [TBL] [Abstract][Full Text] [Related]
53. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leitch HA Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416 [TBL] [Abstract][Full Text] [Related]
54. A prospective phase II randomized study of deferasirox to prevent iatrogenic iron overload in patients undertaking induction/consolidation chemotherapy for acute myeloid leukaemia. Kennedy GA; Morris KL; Subramonpillai E; Curley C; Butler J; Durrant S Br J Haematol; 2013 Jun; 161(6):794-801. PubMed ID: 23590671 [TBL] [Abstract][Full Text] [Related]
55. A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in β-thalassemia major patients receiving desferrioxamine. Moayedi B; Gharagozloo M; Esmaeil N; Maracy MR; Hoorfar H; Jalaeikar M Eur J Haematol; 2013 Mar; 90(3):202-9. PubMed ID: 23278124 [TBL] [Abstract][Full Text] [Related]
56. Pathogenesis and management of iron toxicity in thalassemia. Hershko C Ann N Y Acad Sci; 2010 Aug; 1202():1-9. PubMed ID: 20712765 [TBL] [Abstract][Full Text] [Related]
57. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. Kwiatkowski JL; Cohen AR; Garro J; Alvarez O; Nagasubramanian R; Sarnaik S; Thompson A; Woods GM; Schultz W; Mortier N; Lane P; Mueller B; Yovetich N; Ware RE; Am J Hematol; 2012 Feb; 87(2):221-3. PubMed ID: 22120913 [TBL] [Abstract][Full Text] [Related]
58. Iron overload in myelodysplastic syndromes. Mahesh S; Ginzburg Y; Verma A Leuk Lymphoma; 2008 Mar; 49(3):427-38. PubMed ID: 18297518 [TBL] [Abstract][Full Text] [Related]
59. Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes. Cazzola M; Della Porta MG; Malcovati L Hematology Am Soc Hematol Educ Program; 2008; ():166-75. PubMed ID: 19074076 [TBL] [Abstract][Full Text] [Related]